*To the Editor:* We read with interest the letter written by Seltzer et al[@bib1] about the risk of severe forms of coronavirus disease 2019 (COVID-19) in patients with hidradenitis suppurativa (HS) and would like to share our experience.

COVID-19 is an illness caused by severe acute respiratory syndrome coronavirus 2, which has spread quickly across the globe. This disease has a variable severity spectrum. A severe form develops in a subgroup of patients (especially elderly people and patients with underlying medical comorbidities) characterized by interstitial pneumonia, acute respiratory distress syndrome, and septic shock. HS is a chronic and recurring pathology of the pilosebaceous follicle. It is usually associated with several comorbidities, including obesity, smoking, diabetes mellitus, and cardiovascular pathology, among others, that, at the same time, are risk factors for the development of severe forms of COVID-19.[@bib1] ^,^ [@bib2]

To assess the severity of COVID-19 in HS patients, we reviewed the medical records of the 75 patients with HS who were monitored in our center from February 15 to April 15, 2020. The data were collected directly from the electronic medical record. Verification of data was made by telephone contact with the 75 patients with HS.

Of the 75 patients with HS, 12 received biologic treatment, 30 were treated with nonbiologic systemic drugs, and 33 underwent topical treatment. Data highly suggestive of COVID-19 infection were present in 8 patients, including at least 1 of the following: symptoms of febrile acute respiratory infection, anosmia, ageusia, and compatible analytic or radiographic changes. None of them were tested for diagnostic confirmation, because only those patients who required hospital admission were tested at our center during this time frame. We collected some data from these 8 patients, which are summarized in [Table I](#tbl1){ref-type="table"} . We must specify that, according to the protocol of our center, unilobar pneumonia was not considered a severe form of COVID-19.Table IData of patients with hidradenitis suppurativa with symptoms suggestive of COVID-19VariablePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Age, y6032306950372153Suggestive data of COVID-19Febrile acute respiratory infectionFebrile acute respiratory infection and anosmiaFebrile acute respiratory infectionFebrile acute respiratory infectionFebril acute respiratory infection, ageusia and anosmiaFebril acute respiratory infectionFebril acute respiratory infectionFebril acute respiratory infection and compatible radiographic changesClose contact with confirmed COVID + patientNoNoNoYesNoYesNoNoCOVID-19 risk factorsAge, AH, DM, DL, smokingNoNoAge, AH, DL, IHD, COPD, smoking, obesityAH, DM, obesityNONOAH, smokingTreatment receivedClindamycin 300 mg/12 hDoxycycline 200 mg/24 hEthinylestradiol/levonorgestrel 150/30 mcg/24 hClindamycin 300 mg/12 hAdalimumab, 40 mg/7dDoxycycline, 200 mg/24 hAcitretin, 10 mg/24 hAdalimumab, 40 mg/7 dFirst date symptoms4/6/20203/21/20202/25/20203/25/20203/18/20203/26/20203/13/20203/27/2020End date symptoms4/20/20204/17/20202/28/20204/03/20204/16/20204/8/20203/23/20203/31/2020PneumoniaNoNoNoNoNoNoNoYes, unilobarHospitalizationNoNoNoNoNoNoNoNo[^1]

Regarding treatment, we highlight that there does not seem to be an increased risk of severe COVID-19 infection in our 2 patients with biologic treatment, but the sample size is too small for generalizability. In any case, following the evidence available to date, the current recommendation would be not to withdraw the biologic treatment in patients with HS who present with symptoms of COVID-19 as in other immune-mediated skin pathologies such as psoriasis.[@bib3], [@bib4], [@bib5]

We are aware of the limitations of this study, including the small sample size, the absence of statistical analysis, and the lack of serologies or molecular research to confirm the diagnosis of COVID-19 infection. However, the main interest of this work is that in a population area of the southeast of Madrid very widely affected by the pandemic (with 2176 confirmed severe cases during this period), we observe that there have not been any severe cases within a series of 75 patients with HS, even when these pathologies share risk factors, regardless of the treatment they receive.
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[^1]: *AH*, Arterial hypertension; *COPD*, chronic obstructive pulmonary disease; *COVID-19*, coronavirus disease 2019; *DM*, diabetes mellitus; *DL*, dyslipidemia; *IHD*, ischemic heart disease.
